Printer Friendly

SANDOZ PHARMACEUTICALS CORPORATION ISSUES STATEMENT

 HANOVER, N.J., Sept. 2 /PRNewswire/ -- Sandoz Pharmaceuticals Corporation today issued the following statement regarding a September 2 letter from Public Citizen to the Commissioner of the FDA.
 -- For Sandoz the safety of patients taking any of its medications is paramount, and the company wholeheartedly rejects any allegations that it places business decisions above patients lives.
 -- For the reason, when the issue of Parlodel safety was initially raised, we commissioned an epidemiological study to determine the facts. A thorough analysis of available data has failed to identify a link between Parlodel therapy and the effects alleged by Public Citizen. Sandoz is convinced Parlodel is both an effective and safe medication for women who elected not to breast-feed.
 -- Sandoz strongly recommends that all women capable of breast- feeding do so, but we support the individual rights of women to consult with their physicians in selecting appropriate medical treatment.
 -- Sandoz remains committed to working with the FDA and all other interested parties to ensure the safe and effective use of our products.
 -0- 9/2/93
 /CONTACT: Larry Bauer, 201-503-7895, or William O'Donnell, 201-503-7070, both for Sandoz Pharmaceuticals Corporation/


CO: Sandoz Pharmaceuticals Corporation ST: New Jersey IN: MTC SU:

LD -- NY085 -- 8631 09/02/93 18:14 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 2, 1993
Words:206
Previous Article:IDC HOLDINGS' INDIAN ENTERTAINMENT SYSTEMS, INC. SIGNS CANADIAN GAMING DEVELOPMENT CONTRACTS -- EXPANDS EXISTING SASKATCHEWAN CASINO
Next Article:ROSECLIFF PENSLER PARTNERS L.P. PROPOSES TO ACQUIRE ALL OUTSTANDING COMMON STOCK OF KATY INDUSTRIES
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters